- Home
- HL vs KRYS Comparison
HL vs KRYS Comparison
Compare HL & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HL | KRYS |
|---|---|---|
| Founded | 1891 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 9.6B |
| IPO Year | 2002 | 2017 |
Fundamental Metrics
Financial Performance| Metric | HL | KRYS |
|---|---|---|
| Price | $15.26 | $318.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $22.78 | ★ $395.44 |
| AVG Volume (30 Days) | ★ 34.2M | 264.2K |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | ★ 716.67 | 128.00 |
| EPS | 0.15 | ★ 3.62 |
| Revenue | ★ $645,957,000.00 | $389,130,000.00 |
| Revenue This Year | N/A | $28.02 |
| Revenue Next Year | $29.59 | $28.14 |
| P/E Ratio | $103.57 | ★ $91.20 |
| Revenue Growth | ★ 45.63 | 33.94 |
| 52 Week Low | $11.81 | $183.03 |
| 52 Week High | $34.17 | $382.54 |
Technical Indicators
Market Signals| Indicator | HL | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 33.87 | 39.90 |
| Support Level | $13.98 | $250.34 |
| Resistance Level | $16.43 | $371.16 |
| Average True Range (ATR) | 0.58 | 10.55 |
| MACD | -0.19 | -0.45 |
| Stochastic Oscillator | 22.04 | 9.62 |
Price Performance
Historical ComparisonAbout HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.